id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S18401 R77647 |
Kernizan (Controls exposed to LTG), 2024 | Preterm delivery | during pregnancy (anytime or not specified) | retrospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
0.99 [0.18;5.45] C excluded (control group) |
7/46 2/13 | 9 | 46 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S18348 R77393 |
Kernizan (Controls unexposed, sick), 2024 | Preterm delivery | during pregnancy (anytime or not specified) | retrospective cohort | unexposed, sick | Adjustment: No | 0.41 [0.17;1.00] C | 7/46 42/139 | 49 | 46 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S18385 R77520 |
Kananen - Quetiapine, 2023 | Preterm birth (delivery before the 37th gestational week) | during pregnancy (anytime or not specified) | retrospective cohort | unexposed (general population or NOS) | Adjustment: Yes | 1.30 [0.80;2.12] | 20/152 2,151/35,133 | 2,171 | 152 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S14268 R56085 |
Viguera b, 2023 | Preterm birth | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick | Adjustment: No | 0.99 [0.52;1.88] C | 21/193 21/191 | 42 | 193 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S12454 R46735 |
Wang a (Controls exposed to FGA), 2021 | Preterm birth (<37 gestational weeks) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: No |
0.96 [0.59;1.56] C excluded (control group) |
28/199 59/405 | 87 | 199 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S12453 R46731 |
Wang a (Controls unexposed, NOS), 2021 | Preterm birth (<37 gestational weeks) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: No | 1.83 [1.22;2.72] C | 28/199 33,799/410,545 | 33,827 | 199 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S3851 R8196 |
Ellfolk (Control exposed to FGA), 2019 | Preterm birth 32–36 weeks | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: Yes |
0.87 [0.63;1.20] excluded (control group) |
295/4,225 97/1,576 | 392 | 4,225 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S3818 R8133 |
Ellfolk (Control unexposed), 2019 | Preterm birth 32–36 weeks | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: Yes | 1.29 [1.03;1.62] | 295/4,225 794/21,125 | 1,089 | 4,225 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S3905 R8276 |
Schaffer (Controls unexposed, NOS), 2019 | Preterm (20–36weeks) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed (general population or NOS) excluded | Adjustment: No |
1.97 [1.66;2.34] C excluded (control group) |
154/1,063 7,571/95,523 | 7,725 | 1,063 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S3907 R8285 |
Schaffer (Controls unexposed, sick), 2019 | Preterm (20–36weeks) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed, sick | Adjustment: No | 1.09 [0.86;1.40] C | 154/1,063 148/1,104 | 302 | 1,063 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S3876 R8233 |
Ozturk, 2016 | Preterm birth (<37 weeks) | during pregnancy (anytime or not specified) | retrospective cohort | unexposed (general population or NOS) | Adjustment: No | 1.21 [0.07;22.37] C | 0/12 8/246 | 8 | 12 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S2329 R2696 |
Bellet - Aripiprazole, 2015 | Preterm (< 37 weeks) | 1st trimester | prospective cohort | unexposed (general population or NOS) | Adjustment: No | 2.57 [1.06;6.27] | 11/67 11/155 | 22 | 67 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S2294 R3114 |
Vigod, 2015 | Preterm birth <37 weeks gestation | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed, sick | Adjustment: Yes Matched | 0.99 [0.78;1.26] | 136/923 146/1,021 | 282 | 923 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S2341 R2766 |
Habermann (Control exposed to FGA), 2013 | Preterm (less than 37 gestational weeks) | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
0.54 [0.33;0.87] excluded (control group) |
41/453 36/238 | 77 | 453 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S2385 R2948 |
Habermann (Control unexposed, disease free), 2013 | Preterm (less than 37 gestational weeks) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, disease free | Adjustment: No | 1.06 [0.72;1.56] | 41/453 88/1,014 | 129 | 453 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S2343 R2769 |
Källen, 2013 | Preterm (< 37 weeks) | 2nd and/or 3rd trimester | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: Yes | 1.31 [0.73;1.99] | -/258 -/- | - | 258 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S2286 R2657 |
Sadowski, 2013 | Preterm (gestational age <37weeks) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, disease free | Adjustment: No Matched | 2.64 [0.90;7.75] C | 12/113 5/116 | 17 | 113 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S3842 R8162 |
Hironaka (Control exposed to BZD), 2011 | Preterm labor | during pregnancy (anytime or not specified) | retrospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
1.80 [0.06;54.33] C excluded (control group) |
1/9 0/5 | 1 | 9 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S2334 R2736 |
Hironaka (Control unexposed, disease free), 2011 | Preterm birth (NOS) | during pregnancy (anytime or not specified) | retrospective cohort | unexposed, disease free excluded | Adjustment: No |
6.48 [0.29;145.66] C excluded (control group) |
0/9 2/278 | 2 | 9 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S14447 R57307 |
Hironaka (Control unexposed, sick), 2011 | Preterm birth (NOS) | during pregnancy (anytime or not specified) | retrospective cohort | unexposed, sick | Adjustment: No | 0.29 [0.00;18.96] C | 0/9 0/3 | 0 | 9 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S3849 R8180 |
Lin (Control exposed to FGA), 2010 | Preterm birth | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
0.65 [0.26;1.65] C excluded (control group) |
6/48 35/194 | 41 | 48 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S3848 R8176 |
Lin (Control unexposed, disease free), 2010 | Preterm birth | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, disease free excluded | Adjustment: No |
1.81 [0.76;4.29] C excluded (control group) |
6/48 255/3,480 | 261 | 48 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S2331 R2710 |
Lin (Control unexposed, sick), 2010 | Preterm (< 37 weeks) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, sick | Adjustment: Yes | 1.61 [0.63;4.12] | 6/48 37/454 | 43 | 48 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S2391 R3363 |
Vial (Control exposed to FGA), 2009 | Preterm (NOS) | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No Matched |
0.45 [0.14;1.43] C excluded (control group) |
4/59 14/100 | 18 | 59 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S2390 R3362 |
Vial (Control unexposed, NOS), 2009 | Preterm (NOS) | during pregnancy (anytime or not specified) | prospective cohort | unexposed (general population or NOS) | Adjustment: No | 3.71 [0.80;17.10] C | 4/59 3/156 | 7 | 59 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S2339 R2743 |
Newport, 2007 | Preterm (<37 weeks estimated gestational age) | late pregnancy | prospective cohort | exposed to other treatment, sick | Adjustment: No | 3.08 [0.15;61.39] C | 4/41 0/13 | 4 | 41 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S2305 R3066 |
McKenna, 2005 | Preterm (NOS) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, disease free | Adjustment: No Matched | 1.73 [0.62;4.78] C | 10/77 7/88 | 17 | 77 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 17 studies | 1.24 [1.06;1.45] | 38,009 | 7,938 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Controls unexposed, sick; 2: Controls unexposed, NOS; 3: Control unexposed; 4: Controls unexposed, sick; 5: Control unexposed, disease free; 6: Control unexposed, sick; 7: Control unexposed, sick; 8: Control unexposed, NOS;
Asymetry test p-value = 0.2773 (by Egger's regression)
slope=0.0824 (0.1105); intercept=0.5413 (0.4801); t=1.1275; p=0.2773
excluded 2391, 3849, 3848, 3842, 2334, 2341, 3851, 3905, 12454, 18401